Scientists have failed to indicate that weight-loss surprise drug semaglutide slows the progress of Alzheimer’s illness (AD), as two-year medical trials finish in disappointment for sufferers, medical scientists and drugmaker Novo Nordisk.
In February 2024, we covered the news that researchers on the College of Toronto had discovered an intriguing – and probably groundbreaking – method that GLP-1 agonists had been in a position to scale back inflammatory markers, positioning treatment like Wegovy and Ozempic as potential neurological lifelines. Due to this and different promising indicators in preclinical analysis, there have been naturally a whole lot of eyes on these trials.
Nevertheless, Novo Nordisk has now introduced that the top-line outcomes from its two-year Part 3 trials investigating semaglutide and early-stage symptomatic AD has didn’t ship on its core measure – regardless of some constructive facets when it got here to symptom reduction.
In two randomized, double-blinded trials that includes 3,808 adults, an older model of the corporate’s oral semaglutide was examined for its efficacy and security in lowering the development of AD, in contrast with a placebo. Pre-clinical analysis had scientists cautiously optimistic about yet one more remedy path for semaglutide – and in an space of drugs that desperately wants a significant drug breakthrough.
Whereas Novo Nordisk was effectively conscious that repurposing semaglutide to halt AD development was a protracted shot, there was a whole lot of hope – in addition to money and time – invested in these trials. A number of the disappointment may additionally stem from how we view GLP-1 medicine: if they’ll change the course of weight problems throughout the US, and the world, perhaps they may succeed with AD when nothing else has? In any case, semaglutide has been granted permission to deal with persistent situations like kidney disease and cardiovascular disease, and additional research are its usefulness to fight addiction and rather more. So we could not but be prepared to simply accept that the “miracle drug” does have limitations.
“Based mostly on the numerous unmet want in Alzheimer’s illness in addition to numerous indicative knowledge factors, we felt we had a accountability to discover semaglutide’s potential, regardless of a low probability of success,” Martin Holst Lange, chief scientific officer and govt vp of Analysis and Growth at Novo Nordisk. “Whereas semaglutide didn’t exhibit efficacy in slowing the development of Alzheimer’s illness, the in depth physique of proof supporting semaglutide continues to offer advantages for people with kind 2 diabetes, weight problems and associated comorbidities.”
Semaglutide truly resulted in enhancements in Alzheimer’s disease-related biomarkers throughout the 2 Part 2 trials, however sadly this did not additionally imply it slowed down illness development – which was the main target of the research. Semaglutide did no higher than a placebo in transferring the needle on the Scientific Dementia Score – Sum of Packing containers (CDR-SB) rating, with no significant shift from baseline measures.
Novo Nordisk introduced {that a} one-year extension of the 2 trials would now be discontinued. Their respective top-line outcomes might be offered on the Scientific Trials in Alzheimer’s Illness (CTAD) convention on December 3, and full outcomes might be accessible on the 2026 Alzheimer’s and Parkinson’s Illnesses Conferences in March 2026.
Not surprisingly, the pharmaceutical large’s shares additionally took a giant hit after the announcement.
Supply: Novo Nordisk
